These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12359754)

  • 1. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2.
    Zhang L; Gasper WJ; Stass SA; Ioffe OB; Davis MA; Mixson AJ
    Cancer Res; 2002 Oct; 62(19):5463-9. PubMed ID: 12359754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.
    Würdinger T; Tannous BA; Saydam O; Skog J; Grau S; Soutschek J; Weissleder R; Breakefield XO; Krichevsky AM
    Cancer Cell; 2008 Nov; 14(5):382-93. PubMed ID: 18977327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
    Zhang G; Dass CR; Sumithran E; Di Girolamo N; Sun LQ; Khachigian LM
    J Natl Cancer Inst; 2004 May; 96(9):683-96. PubMed ID: 15126605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme.
    Shen L; Zhou Q; Wang Y; Liao W; Chen Y; Xu Z; Yang L; Sun LQ
    Mol Med; 2013 Nov; 19(1):377-86. PubMed ID: 24306423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
    Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGFR-1 targeted DNAzyme via transcatheter arterial delivery influences tumor vasculature assessed through dynamic contrast-enhanced magnetic resonance imaging.
    Zhang L; Zhao W; Liang C; Yi X; Pei Y; Lin Y; He J; Li W
    Oncol Rep; 2016 Sep; 36(3):1339-44. PubMed ID: 27431919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
    Tang N; Shi L; Yu Z; Dong P; Wang C; Huo X; Zhang B; Huang S; Deng S; Liu K; Ma T; Wang X; Wu L; Ma XC
    Oncotarget; 2016 Jan; 7(3):3533-47. PubMed ID: 26657289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.